In conclusion, we applied a deep-learning method, U-net, for segmenting breast and FGT in MRI in a dataset that includes a variety of MRI protocols and breast densities. Our results showed that U-net-based methods significantly outperformed the existing algorithms and resulted in significantly more accurate breast density computation.
Objectives: We investigated artificial intelligence (AI)-based classification of benign and malignant breast lesions imaged with a multiparametric breast magnetic resonance imaging (MRI) protocol with ultrafast dynamic contrastenhanced MRI, T2-weighted, and diffusion-weighted imaging with apparent diffusion coefficient mapping. Materials and Methods: We analyzed 576 lesions imaged with MRI, including a consecutive set of biopsied malignant (368) and benign (149) lesions, and an additional set of 59 benign lesions proven by follow-up. We used deep learning methods to interpret ultrafast dynamic contrast-enhanced MRI and T2-weighted information. A random forests classifier combined the output with patient information (PI; age and BRCA status) and apparent diffusion coefficient values obtained from diffusion-weighted imaging to perform the final lesion classification. We used receiver operating characteristic (ROC) analysis to evaluate our results. Sensitivity and specificity were compared with the results of the prospective clinical evaluation by radiologists. Results: The area under the ROC curve was 0.811 when only ultrafast dynamics was used. The final AI system that combined all imaging information with PI resulted in an area under the ROC curve of 0.852, significantly higher than the ultrafast dynamics alone (P = 0.002). When operating at the same sensitivity level of radiologists in this dataset, this system produced 19 less false-positives than the number of biopsied benign lesions in our dataset. Conclusions: Use of adjunct imaging and PI has a significant contribution in diagnostic performance of ultrafast breast MRI. The developed AI system for interpretation of multiparametric ultrafast breast MRI may improve specificity.
The authors developed a CADx system for high spatiotemporal resolution DCE-MRI of the breast. This system outperforms a previously proposed system in classifying benign and malignant lesions, while it requires less user interactions.
Current computer-aided detection (CADe) systems for contrast-enhanced breast MRI rely on both spatial information obtained from the early-phase and temporal information obtained from the late-phase of the contrast enhancement. However, late-phase information might not be available in a screening setting, such as in abbreviated MRI protocols, where acquisition is limited to early-phase scans. We used deep learning to develop a CADe system that exploits the spatial information obtained from the early-phase scans. This system uses three-dimensional (3-D) morphological information in the candidate locations and the symmetry information arising from the enhancement differences of the two breasts. We compared the proposed system to a previously developed system, which uses the full dynamic breast MRI protocol. For training and testing, we used 385 MRI scans, containing 161 malignant lesions. Performance was measured by averaging the sensitivity values between 1/8-eight false positives. In our experiments, the proposed system obtained a significantly ([Formula: see text]) higher average sensitivity ([Formula: see text]) compared with that of the previous CADe system ([Formula: see text]). In conclusion, we developed a CADe system that is able to exploit the spatial information obtained from the early-phase scans and can be used in screening programs where abbreviated MRI protocols are used.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.